

# Yosef Yarden

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1714358/publications.pdf>

Version: 2024-02-01

25  
papers

2,933  
citations

304743

22  
h-index

580821

25  
g-index

25  
all docs

25  
docs citations

25  
times ranked

5041  
citing authors

#	ARTICLE	IF	CITATIONS
1	Derailed endocytosis: an emerging feature of cancer. <i>Nature Reviews Cancer</i> , 2008, 8, 835-850.	28.4	652
2	A module of negative feedback regulators defines growth factor signaling. <i>Nature Genetics</i> , 2007, 39, 503-512.	21.4	506
3	Roles for Growth Factors in Cancer Progression. <i>Physiology</i> , 2010, 25, 85-101.	3.1	342
4	CircRNAs: role in human diseases and potential use as biomarkers. <i>Cell Death and Disease</i> , 2021, 12, 468.	6.3	191
5	Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3294-3299.	7.1	161
6	EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. <i>Cancers</i> , 2021, 13, 2748.	3.7	148
7	Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13252-13257.	7.1	135
8	EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors. <i>Science Signaling</i> , 2010, 3, ra43.	3.6	100
9	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1815-1820.	7.1	98
10	EGR1 and the ERK/ERF axis drive mammary cell migration in response to EGF. <i>FASEB Journal</i> , 2012, 26, 1582-1592.	0.5	88
11	LINC01153 is a novel metastasis inhibiting lincRNA suppressed by EGF and downregulated in aggressive breast cancer. <i>EMBO Molecular Medicine</i> , 2016, 8, 1052-1064.	6.9	77
12	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. <i>British Journal of Pharmacology</i> , 2016, 173, 1407-1424.	5.4	56
13	An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors. <i>EMBO Molecular Medicine</i> , 2018, 10, 294-308.	6.9	46
14	Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 576-592.	3.3	43
15	A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. <i>Clinical Cancer Research</i> , 2018, 24, 5610-5621.	7.0	43
16	Proteomic patterns associated with response to breast cancer neoadjuvant treatment. <i>Molecular Systems Biology</i> , 2020, 16, e9443.	7.2	41
17	Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. <i>Cancers</i> , 2020, 12, 2394.	3.7	34
18	Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer. <i>Science Signaling</i> , 2015, 8, ra53.	3.6	33

#	ARTICLE	IF	CITATIONS
19	Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. <i>Seminars in Cell and Developmental Biology</i> , 2016, 50, 164-176.	5.0	31
20	Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2019, 130, 612-624.	8.2	27
21	Cancer Immunotherapy: The Dawn of Antibody Cocktails. <i>Methods in Molecular Biology</i> , 2019, 1904, 11-51.	0.9	25
22	The short and the long: non-coding RNAs and growth factors in cancer progression. <i>Biochemical Society Transactions</i> , 2017, 45, 51-64.	3.4	24
23	Epidermal Growth-Factor “ Induced Transcript Isoform Variation Drives Mammary Cell Migration. <i>PLoS ONE</i> , 2013, 8, e80566.	2.5	15
24	Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models. <i>EMBO Molecular Medicine</i> , 2021, 13, e13144.	6.9	13
25	Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2019, 513, 219-225.	2.1	4